Brokerages Expect Agile Therapeutics Inc (NASDAQ:AGRX) Will Announce Earnings of -$0.08 Per Share

Analysts predict that Agile Therapeutics Inc (NASDAQ:AGRX) will report earnings of ($0.08) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.07). Agile Therapeutics reported earnings per share of ($0.11) in the same quarter last year, which would suggest a positive year over year growth rate of 27.3%. The company is scheduled to issue its next earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.37) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.34). For the next fiscal year, analysts expect that the business will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.77) to $0.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03.

A number of brokerages have recently issued reports on AGRX. ValuEngine cut shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research cut shares of Agile Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $3.45.

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in shares of Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock valued at $108,000 after buying an additional 73,238 shares in the last quarter. BlackRock Inc. raised its stake in shares of Agile Therapeutics by 27.2% in the 2nd quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock valued at $247,000 after buying an additional 36,212 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Agile Therapeutics by 33.3% in the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock valued at $630,000 after buying an additional 104,222 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Agile Therapeutics by 129.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after buying an additional 978,672 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Agile Therapeutics by 5.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock valued at $3,291,000 after buying an additional 120,403 shares in the last quarter. Institutional investors own 43.73% of the company’s stock.

Agile Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $1.13. The company had a trading volume of 11,263 shares, compared to its average volume of 1,233,939. Agile Therapeutics has a 52 week low of $0.51 and a 52 week high of $1.70. The company has a 50 day moving average of $1.18 and a 200-day moving average of $1.31. The firm has a market cap of $51.50 million, a price-to-earnings ratio of -1.93 and a beta of 0.38.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Further Reading: What is a stock buyback?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.